Saturday, 31 October 2026European Markets

BOUSSARD GAVAUDAN Stock Impressive Jump On Tuesday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with BOUSSARD GAVAUDAN (BGHL.AS) rising 11.21% to €23.80 on Tuesday, after three successive sessions in a row of losses. AEX-Index jumped 1.07% to €779.81, following the last session's downward trend on what was an all-around positive trend exchanging session today.

BOUSSARD GAVAUDAN's last close was €21.40, 10.83% below its 52-week high of €24.00.

About BOUSSARD GAVAUDAN

Boussard & Gavaudan Holding Limited is a closed-ended balanced fund of funds launched and managed by Boussard & Gavaudan Asset Management, LP. It invests in a fund which invests in public equity and fixed income markets across the globe. The fund seeks to invest in securities of companies operating across diversified sectors. It primarily invests in units of BG Umbrella Fund Plc - BG Fund, a feeder fund to BG Master Fund Plc, which in turn invests in value stocks of companies and fixed income securities. The fund employs both fundamental and quantitative analysis with a bottom-up security selection approach to create its portfolio. It employs multiple strategies including convertible bond arbitrage, volatility arbitrage, gamma trading, merger arbitrage, special situations, equity long/short, value, capital structure arbitrage, credit long/short, and restructuring/distressed securities strategies to make its investments. Boussard & Gavaudan Holding Limited was formed on October 3, 2006 and is domiciled in the Channel Islands.

Earnings Per Share

As for profitability, BOUSSARD GAVAUDAN has a trailing twelve months EPS of €2.73.

PE Ratio

BOUSSARD GAVAUDAN has a trailing twelve months price to earnings ratio of 8.71. Meaning, the purchaser of the share is investing €8.71 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.21%.

More news about BOUSSARD GAVAUDAN (BGHL.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com